EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma

Hiroki Goto iD, Yoshioki Shiraishi iD, Seiji Okada iD

Exploration of Targeted Anti-tumor Therapy · 28.02.2024 · 5 (1) · 208-224

DOI: 10.37349/etat.2024.00213 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Exploration of Targeted Anti-tumor Therapy, online erschienen am 28.02.2024. Verfasst von Hiroki Goto und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radioisotope and Tumor Pathobiology, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto 860-0811, Japan. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radioimmunotherapy (RIT) is a therapy that combines a radioactive nucleotide with a monoclonal antibody (mAb). RIT enhances the therapeutic effect of mAb and reduces toxicity compared with conventional treatment. The purpose of this review is to summarize the current progress of RIT for treating non-Hodgkin’s lymphoma (NHL) based on recent preclinical and clinical studies. The efficacy of RIT targeting the B-lymphocyte antigen cluster of differentiation 20 (CD20) has been demonstrated in clinical trials. Two radioimmunoconjugates targeting CD20, yttrium-90 (90Y)-ibritumomab-tiuxetan (Zevalin) and iodine-131 (131I)-tositumomab (Bexxar), have been approved in the USA Food and Drug Administration (FDA) for treating relapsed/refractory indolent or transformed NHL in 2002 and 2003, respectively. Although these two radioimmunoconjugates are effective and least toxic, they have not achieved popularity due to increasing access to novel therapies and the complexity of their delivery process. RIT is constantly evolving with the identification of novel targets and novel therapeutic strategies using newer radionuclides such as alpha-particle isotopes. Alpha-particles show very short path lengths and high linear energy transfer. These characteristics provide increased tumor cell-killing activities and reduced non-specific bystander responses on normal tissue. This review also discusses reviewed pre-targeted RIT (PRIT) and immuno-positron emission tomography (PET). PRIT potentially increases the dose of radionuclide delivered to tumors while toxicities to normal tissues are limited. Immuno-PET is a molecular imaging tracer that combines the high sensitivity of PET with the specific targeting capability of mAb. Immuno-PET strategies targeting CD20 and other antigens are currently being developed. The theragnostic approach by immuno-PET will be useful in monitoring the treatment response.

Schlagwörter

Stichwörter der Autor:innen

Radioimmunotherapyimmuno-positron emission tomographymonoclonal antibodynon-Hodgkin’s lymphomapre-targeted radioimmunotherapy

Autor:innen und Institutionen

  • Division of Radioisotope and Tumor Pathobiology, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto 860-0811, Japan.
  • Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan.
  • Radioisotope Center, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto 860-0811, Japan.

ORCID-Profile: Hiroki Goto, Yoshioki Shiraishi, Seiji Okada

Zitieren

APA

Goto, H., Shiraishi, Y., & Okada, S. (2024). Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma. Exploration of Targeted Anti-tumor Therapy, 5(1), 208-224. https://doi.org/10.37349/etat.2024.00213

Vancouver

Goto H, Shiraishi Y, Okada S. Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma. Exploration of Targeted Anti-tumor Therapy. 2024;5(1):208-224. doi:10.37349/etat.2024.00213

BibTeX
@article{Goto2024,
  author = {Goto, Hiroki and Shiraishi, Yoshioki and Okada, Seiji},
  title = {Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma},
  journal = {Exploration of Targeted Anti-tumor Therapy},
  year = {2024},
  volume = {5},
  number = {1},
  pages = {208--224},
  doi = {10.37349/etat.2024.00213}
}
Kostenlos starten →